Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study
- Resource Type
- Article
- Source
- In
Vaccine 29 January 2018 36(5):698-706 - Subject
- Language
- ISSN
- 0264-410X